KalVista Pharmaceuticals, Inc. (KALV)
(Delayed Data from NSDQ)
$15.01 USD
-0.26 (-1.70%)
Updated Dec 10, 2019 04:00 PM ET
Pre-Market: $15.01 0.00 (0.00%) 7:57 PM ET
2-Buy 2
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 2 3 4 5 S&P |
Strong Buy Buy Hold Sell Strong Sell 500 |
24.62% 17.69% 9.40% 5.11% 2.01% 10.65% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
F Value | F Growth | A Momentum | F VGM
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
| Value Score | A |
|---|---|
| Growth Score | A |
| Momentum Score | A |
| VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.
The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.
The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.
Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
KALV (KALV) Quote Overview » More Research » KALV (KALV) Broker Reports
Brokerage Reports
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
| Value Score | A |
|---|---|
| Growth Score | A |
| Momentum Score | A |
| VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.
The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.
The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.
Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.
KalVista Pharmaceuticals, Inc. [KALV]
Reports for Purchase
Showing records 1 - 20 ( 32 total )
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
HAE Study to Readout During 2020, but DME Study Remains on Deck for 4Q19.
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Price: 25.00
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Price: 10.00
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Price: 10.00
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Eying the Potential of KalVistas KVD001 in Diabetic Macular Edema
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Price: 75.00
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Price: 25.00
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Price: 10.00
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
FY1Q Update - With Two Shots on Goal by YE2019, We''re Liking Our Odds
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Price: 25.00
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Pullback in KALV Creates a Buying Opportunity. Reiterate Buy and $30 PT.
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Price: 25.00
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Price: 10.00
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Invitation to Join Kalvista''s Management Call '-' August 19th as 12pm (ET)
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Price: 25.00
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Price: 10.00
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Price: 10.00
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
FY2019 Update Highlights Several Near-Term, Value-Driving Catalysts
Provider: Roth Capital Partners, Inc.
Price: 25.00
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Price: 10.00
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Board Chair Change Comes Ahead of Major Data Readouts in 2H19. Buy $30 PT
Provider: Roth Capital Partners, Inc.
Price: 25.00
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Transfer of Coverage; Maintain Buy Rating and $30PT
Provider: Roth Capital Partners, Inc.
Price: 10.00
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Price: 10.00
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Price: 25.00
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
California Dreamin I: Biotech Stories To Keep An Eye On
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Price: 10.00
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Price: 10.00